Arch Biopartners Inc.
$200,000.00 CAD
≈ 3 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- January 1, 2019 – January 29, 2021
- Reference
- nrc-cnrc:172-2018-2019-Q4-919337
Published purpose
LSALT is a peptide drug and a selective non-enzymatic dipeptidase-1 antagonist and prevents leukocyte adhesion to endothelial cells creating numerous indications for targeting inflammation in the context of microbial and non-microbial (sterile) tissue injury. In pre-clinical mouse models, LSALT has proven efficacious in preventing acute kidney injury induced by ischemia-reperfusion, toxins and sepsis. LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication. Identification of new and more effective versions of LSALT is ongoing.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions